[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100250123":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":30,"responsibleParty":107,"collaborators":18,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":111,"sex":116,"minAge":117,"maxAge":18,"enrollmentInfo":118,"targetDuration":18,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":33,"whyStopped":18,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"Institut Bergonié","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Experimental","Newly obtained biopsy and Blood samples collection",[12],"Procedure: Newly obtained biopsy and Blood samples collection",[14],{"type":15,"name":10,"description":16,"armGroupLabels":17,"otherNames":18},"PROCEDURE","For each patient:\n\n* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling\n* Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.\n\nPatients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.\n\nAll the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report.",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Antoine ITALIANO, MD, PhD","STUDY_CHAIR",[24,27],{"name":21,"role":25,"phone":18,"phoneExt":18,"email":26},"CONTACT","a.italiano@bordeaux.unicancer.fr",{"name":28,"role":25,"phone":18,"phoneExt":18,"email":29},"Simone MATHOULIN-PELISSIER, MD, PhD","s.mathoulin@bordeaux.unicancer.fr",[31,47,61,69,78,90,98],{"facility":32,"status":33,"city":34,"state":18,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Centre Hospitalier de la Côte Basque","RECRUITING","Bayonne","64000","France","FR",{"type":39,"coordinates":40},"Point",[41,42],-1.473,43.49316,{"lat":42,"lon":41},[45],{"name":46,"role":25,"phone":18,"phoneExt":18,"email":18},"Thomas GRELLETY, MD",{"facility":48,"status":33,"city":49,"state":18,"zip":50,"country":36,"countryCode":37,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Clinique Tivoli-Ducos","Bordeaux","33000",{"type":39,"coordinates":52},[53,54],-0.58046,44.84124,{"lat":54,"lon":53},[57,59],{"name":58,"role":25,"phone":18,"phoneExt":18,"email":18},"Delphine GARBAY, MD",{"name":18,"role":25,"phone":18,"phoneExt":18,"email":60},"d.garbay@tivoli-oncologie.fr",{"facility":62,"status":33,"city":49,"state":18,"zip":63,"country":36,"countryCode":37,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Institut Bergonie","33076",{"type":39,"coordinates":65},[53,54],{"lat":54,"lon":53},[68],{"name":21,"role":25,"phone":18,"phoneExt":18,"email":18},{"facility":70,"status":33,"city":49,"state":18,"zip":71,"country":36,"countryCode":37,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Polyclinique Bordeaux Nord Aquitaine","33077",{"type":39,"coordinates":73},[53,54],{"lat":54,"lon":53},[76],{"name":77,"role":25,"phone":18,"phoneExt":18,"email":18},"Camille MAZZA, MD",{"facility":79,"status":80,"city":81,"state":18,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Centre Hospitalier de Pau","NOT_YET_RECRUITING","Pau",{"type":39,"coordinates":83},[84,85],-0.35583,43.31117,{"lat":85,"lon":84},[88],{"name":89,"role":25,"phone":18,"phoneExt":18,"email":18},"Patrick ALDO RENAULT",{"facility":91,"status":33,"city":81,"state":18,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"Clinique Marzet",{"type":39,"coordinates":93},[84,85],{"lat":85,"lon":84},[96],{"name":97,"role":25,"phone":18,"phoneExt":18,"email":18},"Sylvestre LE MOULEC",{"facility":99,"status":100,"city":101,"state":18,"zip":18,"country":36,"countryCode":37,"cosmosGeoPoint":102,"geoPoint":106,"contacts":18},"Centre Eugène Marquis","ACTIVE_NOT_RECRUITING","Rennes",{"type":39,"coordinates":103},[104,105],-1.67431,48.11109,{"lat":105,"lon":104},{"type":108,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100250123","bergonie-institut-profiling--fighting-cancer-by-matching-molecular-alterations-and-drugs-in-early-phase-trials-100250123",false,"NCT02534649","Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials","BIP","Inclusion Criteria:\n\n1. Age ≥ 18 years,\n2. Histology: solid malignant tumor or hematological malignancy,\n3. Deleted MSA9\n4. Deleted MSA9,\n5. Deleted MSA9,\n6. Deleted MSA9,\n7. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code),\n8. Voluntary signed and dated written informed consent prior to any study specific procedure.\n\nExclusion Criteria:\n\n1. Deleted MSA9\n2. Deleted MSA9\n3. Deleted MSA9\n4. Deleted MSA9\n5. Deleted MSA9\n6. Deleted MSA9\n7. Deleted MSA9\n8. Deleted MSA9\n9. Individuals deprived of liberty or placed under guardianship\n10. Pregnant or breast feeding women,\n11. Previous enrolment in the present study.","ALL","18 Years",{"count":119,"type":120},10000,"ESTIMATED","INTERVENTIONAL",[123],"NA","This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease.\n\nIn this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling.\n\nPatients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.",[126,127],"Solid Tumor","Hematological Malignancy",[129,130,131],"Molecular profiling","Genomic alteration","Advanced cancer","2025-10-01",{"date":134,"type":135},"2025-10-02","ACTUAL",{"date":137,"type":135},"2015-12",{"date":139,"type":120},"2029-12",{"name":5,"class":6},7]